First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease

References

• RabeKF, WatzH. Chronic obstructive pulmonary disease. Lancet. 2017;389(10082):1931–1940. doi:10.1016/S0140-6736(17)31222-928513453
   PubMed Web of Science ®Google Scholar
• BuistAS, McBurnieMA, VollmerWM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370(9589):741–750. doi:10.1016/S0140-6736(07)61377-417765523
   PubMed Web of Science ®Google Scholar
• FukuchiY, NishimuraM, IchinoseM, et al. COPD in Japan: the nippon COPD epidemiology study. Respirology. 2004;9(4):458–465. doi:10.1111/j.1440-1843.2004.00637.x15612956
   PubMed Web of Science ®Google Scholar
• WaschkiB, KirstenA, HolzO, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest. 2011;140(2):331–342. doi:10.1378/chest.10-252121273294
   PubMed Web of Science ®Google Scholar
• VogelmeierCF, CrinerGJ, MartinezFJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 Report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. doi:10.1164/rccm.201701-0218PP28128970
   PubMed Web of Science ®Google Scholar
• CalzettaL, RoglianiP, MateraMG, CazzolaM. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of stable COPD. Chest. 2016;149(5):1181–1196. doi:10.1016/j.chest.2016.02.64626923629
   PubMed Web of Science ®Google Scholar
• ZiderAD, WangX, BuhrRG, SirichanaW, BarjaktarevicIZ, CooperCB. Reduced COPD exacerbation risk correlates with improved FEV1: a meta-regression analysis. Chest. 2017;152(3):494–501. doi:10.1016/j.chest.2017.04.17428483609
   PubMed Web of Science ®Google Scholar
• BuhlR, MaltaisF, AbrahamsR, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969–979. doi:10.1183/09031936.0013601425573406
   PubMed Web of Science ®Google Scholar
• WatzH, TroostersT, BeehKM, et al. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2545–2558. doi:10.2147/COPD.S14348828883722
   PubMed Web of Science ®Google Scholar
• TroostersT, MaltaisF, LeidyN, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(8):1021–1032. doi:10.1164/rccm.201706-1288OC29664681
   PubMed Web of Science ®Google Scholar
• IchinoseM, MinakataY, MotegiT, et al. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity. Int J Chron Obstruct Pulmon Dis. 2018;13:1407–1419. doi:10.2147/COPD.S16602329750027
   PubMed Web of Science ®Google Scholar
• MinakataY, MotegiT, UekiJ, et al. Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO ((R)) study. Int J Chron Obstruct Pulmon Dis. 2019;14:1789–1801. doi:10.2147/COPD.S20808131496678
   PubMed Web of Science ®Google Scholar
• PittaF, TroostersT, SpruitMA, ProbstVS, DecramerM, GosselinkR. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171(9):972–977. doi:10.1164/rccm.200407-855OC15665324
   PubMed Web of Science ®Google Scholar
• WatzH, PittaF, RochesterCL, et al. An official European respiratory society statement on physical activity in COPD. Eur Respir J. 2014;44(6):1521–1537. doi:10.1183/09031936.0004681425359358
   PubMed Web of Science ®Google Scholar
• TremblayMS, AubertS, BarnesJD, et al. Sedentary Behavior Research Network (SBRN) terminology consensus project process and outcome. Int J Behav Nutr Phys Act. 2017;14(1):75. doi:10.1186/s12966-017-0525-828599680
   PubMed Web of Science ®Google Scholar
• ByromB, RoweDA. Measuring free-living physical activity in COPD patients: deriving methodology standards for clinical trials through a review of research studies. Contemp Clin Trials. 2016;47:172–184. doi:10.1016/j.cct.2016.01.00626806669
   PubMed Web of Science ®Google Scholar
• SuginoA, MinakataY, KandaM, et al. Validation of a compact motion sensor for the measurement of physical activity in patients with chronic obstructive pulmonary disease. Respiration. 2012;83(4):300–307. doi:10.1159/00033004621912085
   PubMed Web of Science ®Google Scholar
• Sedentary Behaviour Research N. Letter to the editor: standardized use of the terms “sedentary” and “sedentary behaviours”. Appl Physiol Nutr Metab. 2012;37(3):540–542. doi:10.1139/h2012-02422540258
   PubMed Web of Science ®Google Scholar
• MatsumotoK, SekiN, FukuyamaS, et al. Prevalence of asthma with airflow limitation, COPD, and COPD with variable airflow limitation in older subjects in a general Japanese population: the Hisayama Study. Respir Investig. 2015;53(1):22–29. doi:10.1016/j.resinv.2014.08.002
   PubMed Web of Science ®Google Scholar
• ColakY, AfzalS, NordestgaardBG, VestboJ, LangeP. Prognosis of asymptomatic and symptomatic, undiagnosed COPD in the general population in Denmark: a prospective cohort study. Lancet Respir Med. 2017;5(5):426–434. doi:10.1016/S2213-2600(17)30119-428389225
   PubMed Web of Science ®Google Scholar
• TanasescuM, LeitzmannMF, RimmEB, HuFB. Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation. 2003;107(19):2435–2439. doi:10.1161/01.CIR.0000066906.11109.1F12719277
   PubMed Web of Science ®Google Scholar
• FergusonGT, FlezarM, KornS, et al. Efficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv Ther. 2015;32(6):523–536. doi:10.1007/s12325-015-0218-026112656
   PubMed Web of Science ®Google Scholar
• SinghD, GagaM, SchmidtO, et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO (R) studies. Respir Res. 2016;17(1):73. doi:10.1186/s12931-016-0387-727316465
   PubMed Web of Science ®Google Scholar
• WitekTJ Jr, MahlerDA. Minimal important difference of the transition dyspnoea index in a multinational clinical trial. Eur Respir J. 2003;21(2):267–272. doi:10.1183/09031936.03.00068503a12608440
   PubMed Web of Science ®Google Scholar
• DecramerM, AnzuetoA, KerwinE, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–486. doi:10.1016/S2213-2600(14)70065-724835833
   PubMed Web of Science ®Google Scholar
• BatemanED, FergusonGT, BarnesN, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484–1494. doi:10.1183/09031936.0020021223722616
   PubMed Web of Science ®Google Scholar
• DeromE, BrusselleGG, JoosGF. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:3163–3177. doi:10.2147/COPD.S9284028008243
   PubMed Web of Science ®Google Scholar
• CalzettaL, MateraMG, CazzolaM. Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy. Eur J Pharmacol. 2015;761:168–173. doi:10.1016/j.ejphar.2015.05.02025981302
   PubMed Web of Science ®Google Scholar
• IkedaT, AnisuzzamanAS, YoshikiH, et al. Regional quantification of muscarinic acetylcholine receptors and beta-adrenoceptors in human airways. Br J Pharmacol. 2012;166(6):1804–1814. doi:10.1111/j.1476-5381.2012.01881.x22300233
   PubMed Web of Science ®Google Scholar
• CalzettaL, MateraMG, CazzolaM. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Curr Opin Pharmacol. 2018;40:95–103. doi:10.1016/j.coph.2018.03.01129626716
   PubMed Web of Science ®Google Scholar
• HamerM, StamatakisE. Physical activity and mortality in men and women with diagnosed cardiovascular disease. Eur J Cardiovasc Prev Rehabil. 2009;16(2):156–160. doi:10.1097/HJR.0b013e32831f1b7719276984
   PubMedGoogle Scholar
• ParkJ, Ishikawa-TakataK, TanakaS, MekataY, TabataI. Effects of walking speed and step frequency on estimation of physical activity using accelerometers. J Physiol Anthropol. 2011;30(3):119–127. doi:10.2114/jpa2.30.11921636955
   PubMed Web of Science ®Google Scholar
• FurlanettoKC, DonariaL, SchneiderLP, et al. Sedentary behavior is an independent predictor of mortality in subjects with COPD. Respir Care. 2017;62(5):579–587. doi:10.4187/respcare.0530628270544
   PubMed Web of Science ®Google Scholar
• Donaire-GonzalezD, Gimeno-SantosE, BalcellsE, et al. Benefits of physical activity on COPD hospitalisation depend on intensity. Eur Respir J. 2015;46(5):1281–1289. doi:10.1183/13993003.01699-201426206873
   PubMed Web of Science ®Google Scholar
• PiercyKL, TroianoRP, BallardRM, et al. The physical activity guidelines for Americans. JAMA. 2018;320(19):2020–2028. doi:10.1001/jama.2018.1485430418471
   PubMed Web of Science ®Google Scholar
• ShioyaT, SatoS, IwakuraM, et al. Improvement of physical activity in chronic obstructive pulmonary disease by pulmonary rehabilitation and pharmacological treatment. Respir Investig. 2018;56(4):292–306. doi:10.1016/j.resinv.2018.05.002
   PubMed Web of Science ®Google Scholar